Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $268
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. AXSM | 0.00 |
Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:
AXSM) with a Buy and raises the price target from $267 to $268.
